In a significant upward revision, HC Wainwright has raised the target price for Sol-Gel Technologies (NASDAQ: SLGL) from $6.00 to $50.00, as outlined in a research note published on Monday. The firm has issued a “buy” rating for the stock, reflecting increased confidence in the company’s future performance.
In addition to the price target adjustment, HC Wainwright provided estimates for the upcoming earnings of Sol-Gel Technologies. The projections include a loss of $2.09 per share for Q3 2025, a profit of $0.40 per share for Q4 2025, and an overall fiscal year 2025 loss of $0.68 per share. For 2026, forecasts suggest losses of $1.63, $1.74, $1.78, and $1.47 for the first through fourth quarters, leading to an estimated annual loss of $6.60 per share.
Analyst Ratings and Market Response
Other brokerages have also weighed in on Sol-Gel Technologies. On October 8, Weiss Ratings reiterated a “hold (C-)” rating, while Wall Street Zen upgraded the stock to a “buy” rating on September 13. Currently, one analyst rates the stock as a “buy,” while another assigns it a “hold,” resulting in a consensus rating of “Moderate Buy” and an average target price of $50.00.
In recent trading, shares of Sol-Gel Technologies experienced a modest increase of 0.4%. The company last reported its quarterly earnings on August 15, 2023. In that report, Sol-Gel Technologies posted earnings of $4.17 per share, significantly surpassing the consensus estimate of a loss of $0.67 per share by $4.84.
Despite these positive earnings, the company has faced challenges, including a negative return on equity of 11.80% and a net margin of 14.25%. Revenue for the quarter reached $17.26 million, well above analyst expectations of $2.86 million. Analysts anticipate that Sol-Gel Technologies will post an overall loss of $0.28 earnings per share for the current fiscal year.
Company Overview and Product Offerings
Sol-Gel Technologies Ltd., based in Israel, develops topical dermatological treatments for patients with severe skin conditions. Its notable products include Twyneo, a once-daily, non-antibiotic topical cream designed to treat acne vulgaris, and Epsolay, a once-daily topical cream aimed at alleviating symptoms of papulopustular rosacea.
As the market responds to these developments, investors and analysts will be closely monitoring Sol-Gel Technologies’ performance and future earnings reports. The recent price target increase and favorable earnings results indicate a potentially positive trajectory for the company in the coming quarters.
